Three of the trials did not have study acronyms (only trial registration numbers) and ILBS-COVID-02 and PLACID did not have expansions in the original publications. ConCOVID indicates Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease; ConPlas-19, Convalescent Plasma Therapy vs SOC for the Treatment of COVID-19 in Hospitalized Patients; NA, not available; PICP19, Passive Immunization With Convalescent Plasma in Severe COVID-19 Disease; PlasmAr, Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia; RECOVERY, Randomized Evaluation of COVID-19 Therapy.
aThere was no detailed information reported regarding (1) the randomization process or (2) the concealment of randomized assignment.
bThere was no detailed information reported regarding (1) the randomization process, (2) the concealment of randomized assignment, (3) the flow of patients through the trial, and (4) possible deviations from the intended interventions due to the open-label setti
Perrine Janiaud, PhD; Cathrine Axfors, MD, PhD; Andreas M. Schmitt, MD; Viktoria Gloy, PhD; Fahim Ebrahimi, MD, MSc; Matthias Hepprich, MD; Emily R. Smith, ScD, MPH; Noah A. Haber, ScD; Nina Khanna, MD; David Moher, PhD; Steven N. Goodman, MD, PhD; John P. A. Ioannidis, MD, DSc; Lars G. Hemkens, MD, MPH
In this issue of
JAMA, Janiaud et al
1 present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10 722 patients from 6 RCTs (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality (risk ratio, 0.93 [95% CI, 0.63-1.38] for the 4 peer-reviewed RCTs; risk ratio, 1.02 [95% CI, 0.92-1.12] for all 10 RCTs) or with benefit for other clinical outcom
Science’s COVID-19 reporting is supported by the Heising-Simons Foundation.
The world’s largest trial of COVID-19 drugs has produced more good news: The anti-inflammatory drug tocilizumab cut the death risk of people hospitalized with the disease, reduced their need for a mechanical ventilator, and shortened time spent in the hospital, investigators of the United Kingdom’s Recovery trial announced today at a press conference. A preprint about the data has been published on medRxiv.
“This is an incredibly significant result,” says Athimalaipet Ramanan, a rheumatologist at the University of Bristol who was not involved in the study but sits on the steering committee of a tocilizumab trial in India. “This is probably only the second drug that has an impact on mortality,” he says, after the steroid dexamethasone. If the data pan out, it’s “fantastic news,” adds Jason Pogue, a pharmacist at the University of Michigan, Ann Arbor, and president of the Society of Infect
About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company s pipeline candidate to prevent vascular leakage and organ failures is currently being te
Arthritis Drugs Impressive for Severe COVID but Not Magic Cure medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.